LUMO insider filings
LUMOS PHARMA, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-12-13. Screen LUMO transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for LUMO between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — LUMOS PHARMA, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-12-13 | 4 | Hawkins Richard J — Chief Executive Officer, Director | Disposition to issuer (D): 753,093 · Disposition to issuer (D): 4,469 · Disposition to issuer (D): 19,624 (derivative) · Disposition to issuer (D): 35,400 (derivative) · Disposition to issuer (D): 35,400 (derivative) · Disposition to issuer (D): 135,000 (derivative) · +2 more | EDGAR |
| 2024-12-13 | 4 | Zoth Lota S. — Director | Disposition to issuer (D): 2,187 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 5,684 (derivative) · Disposition to issuer (D): 3,431 (derivative) · Disposition to issuer (D): 2,910 (derivative) · +2 more | EDGAR |
| 2024-12-13 | 4 | McKew John C. — Chief Scientific Officer | Disposition to issuer (D): 13,153 · Disposition to issuer (D): 16,000 (derivative) · Disposition to issuer (D): 16,000 (derivative) · Disposition to issuer (D): 6,541 (derivative) · Disposition to issuer (D): 9,583 (derivative) · Disposition to issuer (D): 81,690 (derivative) · +3 more | EDGAR |
| 2024-12-13 | 4 | JOHNSON CHAD ALLEN — Director | Disposition to issuer (D): 1,076 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 5,684 (derivative) · Disposition to issuer (D): 3,431 (derivative) · Disposition to issuer (D): 2,910 (derivative) · +2 more | EDGAR |
| 2024-12-13 | 4 | van Es-Johansson An — Director | Disposition to issuer (D): 1,100 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 3,431 (derivative) · Disposition to issuer (D): 2,910 (derivative) · Disposition to issuer (D): 5,729 (derivative) | EDGAR |
| 2024-12-13 | 4 | Raffin Thomas A. — Director | Disposition to issuer (D): 9,406 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 5,684 (derivative) · Disposition to issuer (D): 3,431 (derivative) · Disposition to issuer (D): 2,910 (derivative) · +2 more | EDGAR |
| 2024-12-13 | 4 | Pitukcheewanont Pisit Duke — Chief Medical Officer | Disposition to issuer (D): 16,836 · Disposition to issuer (D): 3,333 (derivative) · Disposition to issuer (D): 25,500 (derivative) · Disposition to issuer (D): 41,500 (derivative) · Disposition to issuer (D): 29,750 (derivative) | EDGAR |
| 2024-12-13 | 4 | LALANDE KEVIN M. — Director | Disposition to issuer (D): 1,076 · Disposition to issuer (D): 730,446 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 5,684 (derivative) · Disposition to issuer (D): 3,431 (derivative) · +1 more | EDGAR |
| 2024-12-13 | 4 | Schuchart Aaron — Chief Business Officer | Disposition to issuer (D): 8,179 · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 7,805 (derivative) · +1 more | EDGAR |
| 2024-12-13 | 4 | POWERS BRADLEY J — General Counsel | Disposition to issuer (D): 6,307 · Disposition to issuer (D): 27 · Disposition to issuer (D): 11,000 (derivative) · Disposition to issuer (D): 11,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 11,000 (derivative) · +4 more | EDGAR |
| 2024-12-13 | 4 | Lawley Lori D — Chief Financial Officer | Disposition to issuer (D): 12,284 · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 21,250 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 12,000 (derivative) · +4 more | EDGAR |
| 2024-12-13 | 4 | McCracken Joseph S — Director | Disposition to issuer (D): 15,721 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 5,684 (derivative) · Disposition to issuer (D): 3,431 (derivative) · Disposition to issuer (D): 2,910 (derivative) | EDGAR |
| 2024-08-06 | 4 | McKew John C. — Chief Scientific Officer | Sale (S): 3,407 @ $1.89 | EDGAR |
| 2024-08-05 | 4 | Lawley Lori D — Chief Financial Officer | Tax withholding (F): 229 @ $1.79 | EDGAR |
| 2024-08-05 | 4 | McKew John C. — Chief Scientific Officer | Tax withholding (F): 1,593 @ $1.79 | EDGAR |
| 2024-07-03 | 4 | Pitukcheewanont Pisit Duke — Chief Medical Officer | Tax withholding (F): 274 @ $2.26 | EDGAR |
| 2024-06-07 | 4 | van Es-Johansson An — Director | Grant/award (A): 3,328 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | McCracken Joseph S — Director | Grant/award (A): 3,328 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | JOHNSON CHAD ALLEN — Director | Grant/award (A): 3,328 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Zoth Lota S. — Director | Grant/award (A): 3,328 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Raffin Thomas A. — Director | Grant/award (A): 3,328 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | LALANDE KEVIN M. — Director | Grant/award (A): 3,328 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Pitukcheewanont Pisit Duke — Chief Medical Officer | Tax withholding (F): 320 @ $2.25 | EDGAR |
| 2024-04-03 | 4 | Pitukcheewanont Pisit Duke — Chief Medical Officer | Grant/award (A): 6,000 @ $2.84 · Grant/award (A): 41,500 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | POWERS BRADLEY J — General Counsel | Grant/award (A): 900 @ $2.84 · Tax withholding (F): 342 @ $2.84 · Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Lawley Lori D — Chief Financial Officer | Grant/award (A): 1,000 @ $2.84 · Tax withholding (F): 274 @ $2.84 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | McKew John C. — Chief Scientific Officer | Grant/award (A): 2,000 @ $2.84 · Tax withholding (F): 1,036 @ $2.84 · Sale (S): 2,214 @ $2.77 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Hawkins Richard J — Chief Executive Officer, Director | Grant/award (A): 4,500 @ $2.84 · Tax withholding (F): 1,522 @ $2.84 · Grant/award (A): 35,400 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Schuchart Aaron — Chief Business Officer | Grant/award (A): 1,000 @ $2.84 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-02-07 | 4 | McKew John C. — Chief Scientific Officer | Sale (S): 438 @ $3.03 | EDGAR |
| 2024-02-05 | 4 | McKew John C. — Chief Scientific Officer | Tax withholding (F): 366 @ $3.01 | EDGAR |
| 2024-02-05 | 4 | Hawkins Richard J — Chief Executive Officer, Director | Tax withholding (F): 690 @ $3.01 | EDGAR |
| 2024-02-05 | 4 | Lawley Lori D — Chief Financial Officer | Tax withholding (F): 215 @ $3.01 | EDGAR |
| 2024-02-05 | 4 | Schuchart Aaron — Chief Business Officer | Tax withholding (F): 202 @ $3.01 | EDGAR |
| 2024-02-05 | 4 | POWERS BRADLEY J — General Counsel | Tax withholding (F): 240 @ $3.01 | EDGAR |
| 2023-08-03 | 4 | McKew John C. — Chief Scientific Officer | Tax withholding (F): 1,593 @ $3.28 · Sale (S): 3,407 @ $3.21 | EDGAR |
| 2023-08-03 | 4 | Lawley Lori D — Chief Financial Officer | Tax withholding (F): 229 @ $3.28 | EDGAR |
| 2023-05-12 | 4 | Zoth Lota S. — Director | Grant/award (A): 3,345 (derivative) @ $0 | EDGAR |
| 2023-05-12 | 4 | van Es-Johansson An — Director | Grant/award (A): 3,345 (derivative) @ $0 | EDGAR |
| 2023-05-12 | 4 | Raffin Thomas A. — Director | Grant/award (A): 3,345 (derivative) @ $0 | EDGAR |
| 2023-05-12 | 4 | McCracken Joseph S — Director | Grant/award (A): 3,345 (derivative) @ $0 | EDGAR |
| 2023-05-12 | 4 | LALANDE KEVIN M. — Director | Grant/award (A): 3,345 (derivative) @ $0 | EDGAR |
| 2023-05-12 | 4 | JOHNSON CHAD ALLEN — Director | Grant/award (A): 3,345 (derivative) @ $0 | EDGAR |
| 2023-04-04 | 4 | POWERS BRADLEY J — General Counsel | Tax withholding (F): 342 @ $3.31 | EDGAR |
| 2023-04-04 | 4 | McKew John C. — Chief Scientific Officer | Tax withholding (F): 1,036 @ $3.31 · Sale (S): 2,214 @ $3.27 | EDGAR |
| 2023-04-04 | 4 | Lawley Lori D — Chief Financial Officer | Tax withholding (F): 274 @ $3.31 | EDGAR |
| 2023-04-04 | 4 | Hawkins Richard J — Chief Executive Officer, Director | Tax withholding (F): 1,522 @ $3.31 | EDGAR |
| 2023-02-03 | 4 | Lawley Lori D — Chief Financial Officer | Grant/award (A): 1,000 @ $3.52 · Tax withholding (F): 114 @ $3.52 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-02-03 | 4 | Karpf David B — Chief Medical Officer | Grant/award (A): 1,000 @ $3.52 · Tax withholding (F): 36 @ $3.52 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-02-03 | 4 | Hawkins Richard J — Chief Executive Officer, Director | Grant/award (A): 4,500 @ $3.52 · Tax withholding (F): 416 @ $3.52 · Grant/award (A): 35,400 (derivative) @ $0 | EDGAR |
Recent 8-K events — LUMOS PHARMA, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-12-12 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-25 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-01 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-05 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-04 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LUMO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs